MIF (macrophage migration inhibitory factor) is a 12.5 kDa pro-inflammatory cytokine that functions as a pivotal regulator of innate and adaptive immunity 1. Expressed ubiquitously across hematopoietic, epithelial, endothelial, mesenchymal, and neuronal cells, MIF operates in autocrine and paracrine modes by binding multiple receptors including CD74/CD44, CXCR2, CXCR4, and CXCR7, activating downstream pathways such as ERK1/2, AMPK, and AKT 2. MIF promotes pathogen clearance during infections but conversely exacerbates detrimental inflammation and supports cancer progression 1. A critical mechanism involves counteracting glucocorticoid anti-inflammatory activity 3. While MIF possesses dopachrome tautomerase activity in vitro, physiological relevance of this enzymatic function remains unclear 4. Clinically, elevated MIF associates with inflammatory diseases (sepsis, rheumatoid arthritis, spondyloarthritis), organ pathologies (heart failure, acute kidney injury), and autoimmune conditions 25. MIF promotes endothelial cell death during ischemic stroke through RIPK1-mediated pathways 6 and drives CD8+ T cell activation in vitiligo 7. MIF expression and function are regulated by genetic polymorphisms and post-translational modifications, with MIF inhibitors and receptor antagonists showing therapeutic potential across multiple conditions 1.